> It seems to me that this test from India is going in the same direction [as the antigen rapid tests] I think the FELUDA CRISPR/Cas9 test is more of an altern

> It seems to me that this test from India is going in the same direction [as the antigen rapid tests] I think the FELUDA CRISPR/Cas9 test is more of an alternative to PCR with the potential for significantly reduced price per test. Michael Mina's $1 Lick-a-Stick self-administered rapid test is much more of a game changer. The BBC article said that "...the new test had 96% sensitivity and 98% specificity." The fact that we are talking about sensitivity without specifying the viral concentration of the test sample means that Mina's message is not getting through. We need rapid tests that target infectious viral loads, that is, equivalent to PCR Cycle Threshold (CT) of 24 or less. EDIT: changed $5 Lick-a-Stick to $1 - the Abbott BinaxNOW test is $5